Cargando…
Payer reimbursement practices and incentives for improving interpretation of germline genetic testing
Germline genetic testing for inherited cancer risk has shifted to multi-gene panel tests (MGPTs). While MGPTs detect more pathogenic variants, they also detect more variants of uncertain significance (VUSs) that increase the possibility of harms such as unnecessary surgery. Data sharing by laborator...
Autores principales: | Deverka, Patricia, Geary, Janis, Mathews, Charles, Cohen, Matan, Hooker, Gillian, Majumder, Mary, Skvarkova, Zuzana, Cook-Deegan, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332933/ https://www.ncbi.nlm.nih.gov/pubmed/37435610 http://dx.doi.org/10.1093/jlb/lsad020 |
Ejemplares similares
-
Development of an Open Database of Genes Included in Hereditary Cancer Genetic Testing Panels Available From Major Sources in the US
por: Geary, Janis, et al.
Publicado: (2022) -
Fresh takes on five health data sharing domains: Quality, privacy, equity, incentives, and sustainability
por: Guerrini, Christi J., et al.
Publicado: (2023) -
A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
por: Docteur, Elizabeth, et al.
Publicado: (2015) -
Changes in Payer Mix and Physician Reimbursement After the Affordable Care Act and Medicaid Expansion
por: Jones, Christine D., et al.
Publicado: (2015) -
Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts
por: Kannarkat, Joseph T., et al.
Publicado: (2020)